Understanding and Treating Heart Failure With Preserved Ejection Fraction: Novel Mechanisms, Diagnostics and Potential Therapeutics

University of Alberta2 sites in 1 country700 target enrollmentApril 2009

ConditionsHeart Failure

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Heart Failure
Sponsor: University of Alberta
Enrollment: 700
Locations: 2
Primary Endpoint: Percent of patients meeting new diagnostic criteria for HFpEF
Status: Completed
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The objectives of this study are: 1) to design new diagnostic criteria used to accurately define heart failure with preserved ejection fraction (HFpEF); 2) to better define the risk factors associated with HFpEF; 3) to elucidate the clinical, cellular and molecular mechanisms involved with the development and progression of HFpEF; 4) to design and test new therapeutic strategies for patients with HFpEF.

Registry

clinicaltrials.gov

Start Date

April 2009

End Date

May 2, 2022

Last Updated

4 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

University of Alberta

Responsible Party

Principal Investigator

Justin Ezekowitz

Associate Professor, University of Alberta; Director, Heart Function Clinic- Mazankowski Alberta Heart Institute

University of Alberta

Eligibility Criteria

Inclusion Criteria

•Group 1 No clinically overt heart failure
•Group 2 Known coronary artery disease
•Group 3 Known heart failure with preserved ejection fraction
•Group 4 Known heart failure with reduced ejection fraction
•Group 5 Healthy age-matched controls

Exclusion Criteria

•Age \<18 years
•Known malignancy with expected survival \<1 year
•Pregnant or recent pregnancy \<6 months
•Recent event (\<2 weeks since Acute Coronary Syndrome, Heart failure or other admission
•Severe mitral or aortic stenosis